Page last updated: 2024-12-10
strychnobrasiline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
strychnobrasiline: RN refers to (19R)-isomer; from Strychnos sp.; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Strychnos | genus | A plant genus of the family LOGANIACEAE (classified by some botanists as Strychnaceae).[MeSH] | Loganiaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida. They have leaflike appendages at the base of the leafstalks, have terminal flower clusters. Petals have four or five overlapping lobes and the fruit is a capsule containing winged or wingless seeds.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3081468 |
MeSH ID | M0271223 |
Synonyms (6)
Synonym |
---|
34227-00-4 |
(19r)-1-acetyl-20,21-didehydro-17,19-epoxy-4-methyl-3,4-secocuran-3-one |
3,4-secocuran-3-one, 1-acetyl-20,21-didehydro-17,19-epoxy-4-methyl-, (19r)- |
1-acetyl-20,21-didehydro-17,19-epoxy-4-methyl-3,4-secocuran-3-one |
strychnobrasiline |
(9s,10r,13r,14e,21r)-8-acetyl-13,16-dimethyl-12-oxa-8,16-diazapentacyclo[8.8.3.01,9.02,7.014,21]henicosa-2,4,6,14-tetraen-19-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |